APA (7th ed.) Citation

Cattrini, C., Lozano Mejorada, R., Conteduca, V., Ruiz-Vico, M., Lolkema, M., Lorente, D., . . . Castro Marcos, E. (2020). 692TiP BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology, 31, S547. https://doi.org/10.1016/j.annonc.2020.08.2086

Chicago Style (17th ed.) Citation

Cattrini, C., et al. "692TiP BRCA2men: An International, Multicentre, Observational and Ambispective Study to Validate the Predictive Value of Germline BRCA2 Mutations for Selecting the First-line of Treatment in Metastatic Castration-resistant Prostate Cancer (mCRPC)." Annals of Oncology 31 (2020): S547. https://doi.org/10.1016/j.annonc.2020.08.2086.

MLA (9th ed.) Citation

Cattrini, C., et al. "692TiP BRCA2men: An International, Multicentre, Observational and Ambispective Study to Validate the Predictive Value of Germline BRCA2 Mutations for Selecting the First-line of Treatment in Metastatic Castration-resistant Prostate Cancer (mCRPC)." Annals of Oncology, vol. 31, 2020, p. S547, https://doi.org/10.1016/j.annonc.2020.08.2086.